Scarica l'app Stockscreener
104.97
1.31%
-1.39
Dopo l'orario di chiusura:
105.03
0.06
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$106.36
Aprire:
$106.65
Volume 24 ore:
431.37K
Relative Volume:
0.68
Capitalizzazione di mercato:
$5.17B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-16.08
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-6.48%
1M Prestazione:
+0.68%
6M Prestazione:
+1.80%
1 anno Prestazione:
+23.16%
Intervallo 1D:
$104.47
$106.99
Intervallo di 1 settimana:
$102.54
$113.98
Portata 52W:
$72.21
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
104.97 | 5.24B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
How To Trade (AXSM) - news.stocktradersdaily.com
Why Axsome Therapeutics Inc. stock is on top investor watchlistsTremendous wealth creation - jammulinksnews.com
How high can Axsome Therapeutics Inc. stock price go in 2025Consistently profitable trades - jammulinksnews.com
Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN
Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Axsome Therapeutics (NASDAQ:AXSM) Trading Down 5.6%Here's What Happened - MarketBeat
Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest
Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq
What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com
Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s 4th Largest Position - MarketBeat
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Mizuho reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit - TipRanks
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by New York State Common Retirement Fund - MarketBeat
Lindbrook Capital LLC Sells 14,103 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
What analysts say about Axsome Therapeutics Inc. stockExtraordinary market timing - jammulinksnews.com
Axsome Therapeutics Inc. Stock Analysis and ForecastUnstoppable trading performance - Autocar Professional
Axsome Therapeutics Rings the Opening Bell - Nasdaq
Axsome Therapeutics hosts frontiers in Brain Health R&D Day - TipRanks
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - Lelezard
Axsome Therapeutics: A CNS Pipeline with High-Impact Catalysts for Long-Term Growth - AInvest
Axsome Therapeutics Hosts R&D Day to Present Comprehensive Data on CNS Pipeline Targeting Alzheimer’s Disease, Depression, Narcolepsy, Fibromyalgia, ADHD, and Smoking Cessation - Nasdaq
Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments - Stock Titan
Axsome Celebrates New CNS Drug Launch with NASDAQ Bell Ringing, Unveils Brain Health Pipeline - Stock Titan
Bank of New York Mellon Corp Has $15.28 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Issues Negative Outlook for AXSM Earnings - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Mizuho reiterates Outperform rating on Axsome Therapeutics stock ahead of R&D Day - Investing.com Australia
Edgestream Partners L.P. Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 4.5% this past week - simplywall.st
Alps Advisors Inc. Has $3.78 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Long Term Investment Analysis - news.stocktradersdaily.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Iridian Asset Management LLC CT - MarketBeat
Penserra Capital Management LLC Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Stocks Showing Improving Market Leadership: Axsome Therapeutics Earns 85 RS Rating - MSN
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating - MSN
Axsome Therapeutics (AXSM) Soars 5.77% on Positive Analyst Ratings - AInvest
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 - 富途牛牛
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - The Manila Times
Axsome Therapeutics Scheduled to Report Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Nasdaq
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics shares rise 1.08% intraday as RBC Capital Markets maintains its stance on the biopharma company. - AInvest
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):